Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 20/20 | 1.00 |
| ▸ | PDCD1LG2 | Q9BQ51 | 15/20 | 1.00 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21506846 | 1.00 | CD274 (1.00) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL21507212 | 0.92 | CD274 (1.00) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL21563303 | 0.90 | CD274 (0.81) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL21507165 | 0.88 | CD274 (1.00) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL29982390 | 0.88 | CD274 (0.78) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL27079333 | 0.88 | CD274 (0.78) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL27079120 | 0.88 | CD274 (0.78) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL27079113 | 0.88 | CD274 (0.78) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL29982687 | 0.88 | CD274 (0.78) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL21507452 | 0.87 | PDCD1LG2 (1.00) | CD274PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4600247-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-3781556-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-06-18 | — | — | EP | disclosed |
| US-10899735-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20190345131-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899735-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | CD274 2/4885PDCD1LG2 3/4885PDCD1 1/4885 |
| US-20190345131-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CD274 2/4885PDCD1LG2 3/4885PDCD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.